| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | -0.095 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.02 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |